WO2007120689A3 - Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual - Google Patents

Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual Download PDF

Info

Publication number
WO2007120689A3
WO2007120689A3 PCT/US2007/008902 US2007008902W WO2007120689A3 WO 2007120689 A3 WO2007120689 A3 WO 2007120689A3 US 2007008902 W US2007008902 W US 2007008902W WO 2007120689 A3 WO2007120689 A3 WO 2007120689A3
Authority
WO
WIPO (PCT)
Prior art keywords
individual
bone mass
gpr119 receptor
methods
compounds useful
Prior art date
Application number
PCT/US2007/008902
Other languages
French (fr)
Other versions
WO2007120689A2 (en
Inventor
Zhi-Liang Chu
James N Leonard
Original Assignee
Arena Pharm Inc
Zhi-Liang Chu
James N Leonard
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MEP-273/08A priority Critical patent/MEP27308A/en
Priority to DK07755238.8T priority patent/DK1971862T3/en
Priority to SI200730474T priority patent/SI1971862T1/en
Priority to PL07755238T priority patent/PL1971862T3/en
Priority to UAA200813041A priority patent/UA97479C2/en
Priority to US11/989,037 priority patent/US7833730B2/en
Priority to CA2618488A priority patent/CA2618488C/en
Priority to AT07755238T priority patent/ATE487940T1/en
Priority to EP07755238A priority patent/EP1971862B1/en
Priority to NZ571110A priority patent/NZ571110A/en
Priority to EA200870424A priority patent/EA016041B1/en
Priority to AU2007238805A priority patent/AU2007238805B2/en
Priority to DE602007010420T priority patent/DE602007010420D1/en
Priority to MX2008013120A priority patent/MX2008013120A/en
Application filed by Arena Pharm Inc, Zhi-Liang Chu, James N Leonard filed Critical Arena Pharm Inc
Priority to BRPI0710597-5A priority patent/BRPI0710597A2/en
Priority to KR1020087027461A priority patent/KR101281962B1/en
Priority to CN2007800127142A priority patent/CN101421618B/en
Priority to JP2009505445A priority patent/JP4521838B2/en
Publication of WO2007120689A2 publication Critical patent/WO2007120689A2/en
Publication of WO2007120689A3 publication Critical patent/WO2007120689A3/en
Priority to ZA2008/07997A priority patent/ZA200807997B/en
Priority to TNP2008000396A priority patent/TNSN08396A1/en
Priority to HK08112333.3A priority patent/HK1117911A1/en
Priority to NO20084746A priority patent/NO20084746L/en
Priority to US12/700,423 priority patent/US8026212B2/en
Priority to US12/700,443 priority patent/US8017574B2/en
Priority to US12/700,394 priority patent/US8026074B2/en
Priority to HR20110068T priority patent/HRP20110068T1/en
Priority to US13/195,177 priority patent/US8580526B2/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/108—Osteoporosis

Abstract

The present invention relates to methods of using GPR119 receptor to identify compounds useful for increasing bone mass in an individual. Agonists of GPR119 receptor are useful as therapeutic agents for treating or preventing a condition characterized by low bone mass, such as osteoporosis, and for increasing bone mass in an individual. Agonists of GPR119 receptor promote bone formation in an individual.
PCT/US2007/008902 2006-04-11 2007-04-10 Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual WO2007120689A2 (en)

Priority Applications (27)

Application Number Priority Date Filing Date Title
BRPI0710597-5A BRPI0710597A2 (en) 2006-04-11 2007-04-10 method of using the gpr119 receptor to identify compounds useful for bone mass augmentation in an individual
DK07755238.8T DK1971862T3 (en) 2006-04-11 2007-04-10 Methods of Using GPR119 Receptor to Identify Compounds Useful for Increasing Bone Mass in a Person
PL07755238T PL1971862T3 (en) 2006-04-11 2007-04-10 Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual
UAA200813041A UA97479C2 (en) 2006-04-11 2007-04-10 Use of g-protein-combined receptor (gpcr) for identification of means that enhance secretion of glucose-dependent insulinotropic peptide (gip)
US11/989,037 US7833730B2 (en) 2006-04-11 2007-04-10 Methods of using GPR119 to identify compounds useful for increasing bone mass in an individual
CA2618488A CA2618488C (en) 2006-04-11 2007-04-10 Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual
AT07755238T ATE487940T1 (en) 2006-04-11 2007-04-10 METHOD OF USING THE GPR119 RECEPTOR TO IDENTIFY COMPOUNDS INCREASE BONE MASS IN A PERSON
EP07755238A EP1971862B1 (en) 2006-04-11 2007-04-10 Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual
NZ571110A NZ571110A (en) 2006-04-11 2007-04-10 Methods of using GPR119 receptor to identify Glucose-dependent Insulinotropic Peptide (GIP) secretagogue compounds useful for increasing bone mass in an individual
EA200870424A EA016041B1 (en) 2006-04-11 2007-04-10 Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual
AU2007238805A AU2007238805B2 (en) 2006-04-11 2007-04-10 Methods of using GPR119 receptor to identify compounds useful for increasing bone mass in an individual
DE602007010420T DE602007010420D1 (en) 2006-04-11 2007-04-10 METHOD OF USE OF THE GPR119 RECEPTOR FOR IDENTIFYING COMPOUNDS FOR INCREASING THE BONE MASS IN ONE PERSON
MX2008013120A MX2008013120A (en) 2006-04-11 2007-04-10 Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual.
MEP-273/08A MEP27308A (en) 2006-04-11 2007-04-10 Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual
SI200730474T SI1971862T1 (en) 2006-04-11 2007-04-10 Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual
KR1020087027461A KR101281962B1 (en) 2006-04-11 2007-04-10 Methods of using GPR119 receptor to identify compounds useful for increasing bone mass in an individual
CN2007800127142A CN101421618B (en) 2006-04-11 2007-04-10 Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual
JP2009505445A JP4521838B2 (en) 2006-04-11 2007-04-10 Methods of using the GPR119 receptor to identify compounds that are useful for increasing bone mass in an individual
ZA2008/07997A ZA200807997B (en) 2006-04-11 2008-09-17 Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual
TNP2008000396A TNSN08396A1 (en) 2006-04-11 2008-10-09 Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual
HK08112333.3A HK1117911A1 (en) 2006-04-11 2008-11-10 Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual
NO20084746A NO20084746L (en) 2006-04-11 2008-11-10 Method of using GPR119 receptor to identify compounds useful for increasing bone mass in an individual
US12/700,423 US8026212B2 (en) 2006-04-11 2010-02-04 Methods of preparing pharmaceutical compositions comprising GPR119 agonists having the effect of glucose-dependent insulinotropic peptide secretatgogues
US12/700,443 US8017574B2 (en) 2006-04-11 2010-02-04 Methods of preparing pharmaceutical compositions comprising GPR119 agonists having the effect of glucose-dependent insulinotropic peptide secretagogues
US12/700,394 US8026074B2 (en) 2006-04-11 2010-02-04 Methods of using GPR119 to identify compounds useful for increasing bone mass in an individual
HR20110068T HRP20110068T1 (en) 2006-04-11 2011-01-28 Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual
US13/195,177 US8580526B2 (en) 2006-04-11 2011-08-01 Methods of using GPR119 receptor to identify compounds which stimulate glucose-dependent insulinotropic peptide secretion

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79155006P 2006-04-11 2006-04-11
US60/791,550 2006-04-11

Related Child Applications (4)

Application Number Title Priority Date Filing Date
US11/989,037 A-371-Of-International US7833730B2 (en) 2006-04-11 2007-04-10 Methods of using GPR119 to identify compounds useful for increasing bone mass in an individual
US12/700,443 Continuation US8017574B2 (en) 2006-04-11 2010-02-04 Methods of preparing pharmaceutical compositions comprising GPR119 agonists having the effect of glucose-dependent insulinotropic peptide secretagogues
US12/700,423 Continuation US8026212B2 (en) 2006-04-11 2010-02-04 Methods of preparing pharmaceutical compositions comprising GPR119 agonists having the effect of glucose-dependent insulinotropic peptide secretatgogues
US12/700,394 Continuation US8026074B2 (en) 2006-04-11 2010-02-04 Methods of using GPR119 to identify compounds useful for increasing bone mass in an individual

Publications (2)

Publication Number Publication Date
WO2007120689A2 WO2007120689A2 (en) 2007-10-25
WO2007120689A3 true WO2007120689A3 (en) 2008-05-29

Family

ID=38442009

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/008902 WO2007120689A2 (en) 2006-04-11 2007-04-10 Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual

Country Status (36)

Country Link
US (5) US7833730B2 (en)
EP (4) EP1971862B1 (en)
JP (6) JP4521838B2 (en)
KR (1) KR101281962B1 (en)
CN (3) CN101421618B (en)
AR (1) AR060406A1 (en)
AT (1) ATE487940T1 (en)
AU (1) AU2007238805B2 (en)
BR (1) BRPI0710597A2 (en)
CA (1) CA2618488C (en)
CL (1) CL2007001011A1 (en)
CR (1) CR10337A (en)
CY (1) CY1111123T1 (en)
DE (1) DE602007010420D1 (en)
DK (1) DK1971862T3 (en)
EA (2) EA016041B1 (en)
EC (1) ECSP088817A (en)
ES (1) ES2354390T3 (en)
GT (1) GT200800207A (en)
HK (1) HK1117911A1 (en)
HR (1) HRP20110068T1 (en)
MA (1) MA30555B1 (en)
ME (1) MEP27308A (en)
MX (1) MX2008013120A (en)
NO (1) NO20084746L (en)
NZ (1) NZ571110A (en)
PL (1) PL1971862T3 (en)
PT (1) PT1971862E (en)
RS (1) RS51745B (en)
SG (1) SG10201404220TA (en)
SI (1) SI1971862T1 (en)
TN (1) TNSN08396A1 (en)
TW (1) TWI409458B (en)
UA (1) UA97479C2 (en)
WO (1) WO2007120689A2 (en)
ZA (1) ZA200807997B (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS20050532A (en) 2003-01-14 2007-12-31 Arena Pharmaceuticals Inc., 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
DOP2006000008A (en) * 2005-01-10 2006-08-31 Arena Pharm Inc COMBINED THERAPY FOR THE TREATMENT OF DIABETES AND RELATED AFFECTIONS AND FOR THE TREATMENT OF AFFECTIONS THAT IMPROVE THROUGH AN INCREASE IN THE BLOOD CONCENTRATION OF GLP-1
PE20071221A1 (en) 2006-04-11 2007-12-14 Arena Pharm Inc GPR119 RECEPTOR AGONISTS IN METHODS TO INCREASE BONE MASS AND TO TREAT OSTEOPOROSIS AND OTHER CONDITIONS CHARACTERIZED BY LOW BONE MASS, AND COMBINED THERAPY RELATED TO THESE AGONISTS
EP1971862B1 (en) 2006-04-11 2010-11-10 Arena Pharmaceuticals, Inc. Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual
CN101801954B (en) 2007-09-20 2013-10-09 Irm责任有限公司 Compounds and compositions as modulators of GPR119 activity
EP2146210A1 (en) * 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
NZ596445A (en) 2009-06-24 2013-04-26 Boehringer Ingelheim Int New compounds, pharmaceutical composition and methods relating thereto
JP2012530758A (en) 2009-06-24 2012-12-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Novel compounds, pharmaceutical compositions and methods relating thereto
AR077642A1 (en) 2009-07-09 2011-09-14 Arena Pharm Inc METABOLISM MODULATORS AND THE TREATMENT OF DISORDERS RELATED TO THE SAME
WO2011113947A1 (en) 2010-03-18 2011-09-22 Boehringer Ingelheim International Gmbh Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
EP2556056A1 (en) 2010-04-06 2013-02-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012025811A1 (en) 2010-08-23 2012-03-01 Lupin Limited Indolylpyrimidines as modulators of gpr119
SG188548A1 (en) 2010-09-22 2013-04-30 Arena Pharm Inc Modulators of the gpr119 receptor and the treatment of disorders related thereto
AU2011333472A1 (en) 2010-11-26 2013-06-06 Lupin Limited Bicyclic GPR119 modulators
WO2012135570A1 (en) 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20140066369A1 (en) 2011-04-19 2014-03-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145603A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145604A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012170867A1 (en) 2011-06-09 2012-12-13 Rhizen Pharmaceuticals Sa Novel compounds as modulators of gpr-119
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
JP2015522080A (en) 2012-07-11 2015-08-03 エルセリクス セラピューティクス インコーポレイテッド Compositions for reducing cardiovascular metabolic risk comprising statins, biguanides, and additional agents
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
NZ734220A (en) 2015-01-06 2022-01-28 Arena Pharm Inc Methods of treating conditions related to the s1p1 receptor
KR200481746Y1 (en) 2015-01-21 2016-11-04 큰길엔터프라이즈 주식회사 Natural humidifier
CN108349891B (en) 2015-06-22 2022-04-05 艾尼纳制药公司 Crystalline L-arginine salt of a compound for use in S1P1 receptor-related disorders
WO2018151873A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
WO2018236896A1 (en) 2017-06-19 2018-12-27 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of nafld and nash
JP2023526625A (en) 2020-05-19 2023-06-22 キャリーオペ，インク． AMPK Activator
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001087929A2 (en) * 2000-05-18 2001-11-22 Bayer Aktiengesellschaft Regulation of human dopamine-like g protein-coupled receptor
US6410508B1 (en) * 1998-10-07 2002-06-25 Med College Georgia Res Inst Glucose-dependent insulinotropic peptide for use as an osteotropic hormone
WO2005007647A1 (en) * 2003-07-11 2005-01-27 Arena Pharmaceuticals, Inc. Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto

Family Cites Families (188)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4704362A (en) * 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4495002A (en) * 1981-05-27 1985-01-22 Westinghouse Electric Corp. Three-step treatment of stainless steels having metastable austenitic and martensitic phases to increase resistance to chloride corrosion
US5462856A (en) * 1990-07-19 1995-10-31 Bunsen Rush Laboratories, Inc. Methods for identifying chemicals that act as agonists or antagonists for receptors and other proteins involved in signal transduction via pathways that utilize G-proteins
CA2121369C (en) 1991-10-22 2003-04-29 William W. Bachovchin Inhibitors of dipeptidyl-aminopeptidase type iv
MX9206628A (en) 1991-11-22 1993-05-01 Boehringer Ingelheim Pharma PROLINABORONATE ESTER AND METHOD FOR ITS PREPARATION.
US6100042A (en) 1993-03-31 2000-08-08 Cadus Pharmaceutical Corporation Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor
DE19616486C5 (en) 1996-04-25 2016-06-30 Royalty Pharma Collection Trust Method for lowering the blood glucose level in mammals
US20020006899A1 (en) 1998-10-06 2002-01-17 Pospisilik Andrew J. Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
US6040145A (en) 1997-05-07 2000-03-21 Tufts University Potentiation of the immune response
US6100234A (en) 1997-05-07 2000-08-08 Tufts University Treatment of HIV
US6183974B1 (en) 1997-07-31 2001-02-06 The General Hospital Corporation Screening assays for G protein coupled receptor agonists and antagonists
GB9719496D0 (en) 1997-09-13 1997-11-19 Glaxo Group Ltd G protien chimeras
WO1999025719A1 (en) 1997-11-18 1999-05-27 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Novel physiologically active substance sulphostin, process for producing the same, and use thereof
WO1999038501A2 (en) 1998-02-02 1999-08-05 Trustees Of Tufts College Method of regulating glucose metabolism, and reagents related thereto
US5922576A (en) * 1998-02-27 1999-07-13 The John Hopkins University Simplified system for generating recombinant adenoviruses
US6304621B1 (en) 1998-05-13 2001-10-16 Broadcom Corporation Multi-mode variable rate digital cable receiver
DE19823831A1 (en) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim New pharmaceutical use of isoleucyl thiazolidide and its salts
DE19828113A1 (en) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs of Dipeptidyl Peptidase IV Inhibitors
DE19828114A1 (en) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs of unstable inhibitors of dipeptidyl peptidase IV
DE19834591A1 (en) 1998-07-31 2000-02-03 Probiodrug Ges Fuer Arzneim Use of substances that decrease the activity of dipeptidyl peptidase IV to increase blood sugar levels, e.g. for treating hypoglycemia
AU5190499A (en) 1998-08-06 2000-02-28 Shmuel Peltz Method and appliances for electrostimulation
KR20010079669A (en) 1998-08-21 2001-08-22 바바라 피. 월너 Regulation of Substrate Activity
JP2002523090A (en) 1998-09-01 2002-07-30 ビーエーエスエフ アクチェンゲゼルシャフト Enhanced functional expression of heterologous G protein-coupled receptors
US6242422B1 (en) 1998-10-22 2001-06-05 Idun Pharmacueticals, Inc. (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
KR100926209B1 (en) 1998-11-20 2009-11-09 아레나 파마슈티칼스, 인크. Human Orphan G Protein-Coupled Receptors
CO5150173A1 (en) 1998-12-10 2002-04-29 Novartis Ag COMPOUNDS N- (REPLACED GLYCLE) -2-DIPEPTIDYL-IV PEPTIDASE INHIBITING CYANOPIRROLIDINS (DPP-IV) WHICH ARE EFFECTIVE IN THE TREATMENT OF CONDITIONS MEDIATED BY DPP-IV INHIBITION
JP2000191616A (en) 1998-12-24 2000-07-11 Senju Pharmaceut Co Ltd New peptidylaldehyde derivative and medicine containing the same
US20030125539A1 (en) * 1999-02-22 2003-07-03 Synaptic Pharmaceutical Corporation DNA encoding SNORF25 receptor
US6221660B1 (en) * 1999-02-22 2001-04-24 Synaptic Pharmaceutical Corporation DNA encoding SNORF25 receptor
JP4121215B2 (en) 1999-05-17 2008-07-23 財団法人微生物化学研究会 Sulfostin analog, and method for producing sulfostine and its analog
JP4028135B2 (en) 1999-05-27 2007-12-26 本田技研工業株式会社 Object detection device
US6617340B1 (en) 1999-07-29 2003-09-09 Novartis Ag N-(substituted glycyl)-pyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
DE19940130A1 (en) 1999-08-24 2001-03-01 Probiodrug Ges Fuer Arzneim New effectors of Dipeptidyl Peptidase IV for topical use
US6653064B1 (en) 1999-09-23 2003-11-25 Boehringer Ingelheim International Gmbh Method for identifying compounds useful in the therapy of bone disorders
GB9923177D0 (en) 1999-09-30 1999-12-01 Pfizer Ltd Novel polypeptide
JP2003535034A (en) 1999-11-12 2003-11-25 ギルフォード ファーマシューティカルズ インコーポレイテッド Dipeptidyl peptidase IV inhibitors and methods for producing and using dipeptidyl peptidase IV inhibitors
US6380398B2 (en) 2000-01-04 2002-04-30 Novo Nordisk A/S Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV
DE60132723T2 (en) 2000-01-21 2009-01-29 Novartis Pharma Ag Compositions consisting of dipeptidyl peptidase IV inhibitors and antidiabetics
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
US6608038B2 (en) 2000-03-15 2003-08-19 Novartis Ag Methods and compositions for treatment of diabetes and related conditions via gene therapy
EP2336169A1 (en) 2000-04-21 2011-06-22 New England Medical Center Hospital G protein coupled receptor (GPCR) agonists and antagonists and methods of activating and inhibiting GPCR using the same
GB0010183D0 (en) 2000-04-26 2000-06-14 Ferring Bv Inhibitors of dipeptidyl peptidase IV
GB0010188D0 (en) 2000-04-26 2000-06-14 Ferring Bv Inhibitors of dipeptidyl peptidase IV
US6432969B1 (en) 2000-06-13 2002-08-13 Novartis Ag N-(substituted glycyl)-2 cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
TW583185B (en) 2000-06-13 2004-04-11 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines and pharmaceutical composition for inhibiting dipeptidyl peptidase-IV (DPP-IV) or for the prevention or treatment of diseases or conditions associated with elevated levels of DPP-IV comprising the same
AU6895801A (en) 2000-07-04 2002-01-14 Novo Nordisk As Heterocyclic compounds, which are inhibitors of the enzyme dpp-iv
AU7705601A (en) 2000-07-25 2002-02-05 Merck & Co Inc N-substituted indoles useful in the treatment of diabetes
WO2002014271A1 (en) 2000-08-10 2002-02-21 Mitsubishi Pharma Corporation Proline derivatives and use thereof as drugs
US20040005555A1 (en) 2000-08-31 2004-01-08 Rothman Richard E. Molecular diagnosis of bactermia
TWI290919B (en) 2000-10-06 2007-12-11 Tanabe Seiyaku Co Nitrogen-containing five-membered ring compound, a pharmacologically permissible salt thereof and the method for producing the same
JP2004035574A (en) 2000-10-06 2004-02-05 Tanabe Seiyaku Co Ltd Aliphatic nitrogenous five-membered ring compound
JP4329290B2 (en) 2000-10-06 2009-09-09 田辺三菱製薬株式会社 Aliphatic nitrogen-containing five-membered ring compounds
JP4329291B2 (en) 2000-10-06 2009-09-09 田辺三菱製薬株式会社 Nitrogen-containing five-membered ring compounds
TWI243162B (en) 2000-11-10 2005-11-11 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives
AU1989002A (en) 2000-11-27 2002-06-03 Arena Pharm Inc Endogenous and non-endogenous versions of human g protein-coupled receptors
ES2280435T3 (en) 2000-12-01 2007-09-16 Astellas Pharma Inc. METHOD OF EXPLORATION OF REMEDIES FOR DIABETES.
US20040180925A1 (en) 2000-12-27 2004-09-16 Kenji Matsuno Dipeptidylpeptidase-IV inhibitor
JP4823431B2 (en) 2001-01-30 2011-11-24 東レ・ダウコーニング株式会社 Room temperature curable silicone rubber composition
JP4213390B2 (en) 2001-02-02 2009-01-21 武田薬品工業株式会社 Fused heterocyclic compounds
DK1953162T3 (en) 2001-02-24 2012-09-10 Boehringer Ingelheim Pharma Xanthine derivatives, their preparation and their use as a drug.
JP2002265439A (en) 2001-03-08 2002-09-18 Mitsubishi Pharma Corp Cyanopyrrolidine derivative and its use for medicine
ATE395912T1 (en) 2001-03-27 2008-06-15 Merck & Co Inc DIPEPTIDYLPEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
WO2002080860A2 (en) 2001-03-27 2002-10-17 The Regents Of The University Of California Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism
FR2822826B1 (en) 2001-03-28 2003-05-09 Servier Lab NOVEL ALPHA-AMINO ACID SULPHONYL DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
US6573287B2 (en) 2001-04-12 2003-06-03 Bristo-Myers Squibb Company 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
US20020192206A1 (en) 2001-05-05 2002-12-19 Kozarov Emil V. Methods and compositions for angioproliferative disorder treatment
FR2824825B1 (en) 2001-05-15 2005-05-06 Servier Lab NOVEL ALPHA-AMINOACID DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
JP2003000977A (en) 2001-06-26 2003-01-07 Juki Corp Bag-cloth feeder of binding sewing machine
US20030130199A1 (en) 2001-06-27 2003-07-10 Von Hoersten Stephan Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
US7368421B2 (en) 2001-06-27 2008-05-06 Probiodrug Ag Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis
US6869947B2 (en) 2001-07-03 2005-03-22 Novo Nordisk A/S Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US6740250B2 (en) 2001-07-13 2004-05-25 Hazard Control Technologies Fire suppressant having foam stabilizer
DE10143840A1 (en) 2001-09-06 2003-03-27 Probiodrug Ag New acylated hydroxamates useful for the treatment of e.g. wound healing
US6844316B2 (en) 2001-09-06 2005-01-18 Probiodrug Ag Inhibitors of dipeptidyl peptidase I
CN100341862C (en) 2001-09-14 2007-10-10 三菱制药株式会社 Thiazolidine derivative and medicinal use thereof
JPWO2003026661A1 (en) 2001-09-14 2005-01-06 山之内製薬株式会社 Insulin secretion promoter and novel pyrimidine derivatives
JP2005509603A (en) 2001-09-19 2005-04-14 ノボ　ノルディスク　アクティーゼルスカブ Heterocyclic compounds that are inhibitors of the DPP-IV enzyme
US7238671B2 (en) 2001-10-18 2007-07-03 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
JP2005514337A (en) 2001-10-18 2005-05-19 ブリストル−マイヤーズ　スクイブ　カンパニー Human glucagon-like peptide-1 mimics and their use in the treatment of diabetes and related diseases
GB0125446D0 (en) 2001-10-23 2001-12-12 Ferring Bv Novel anti-diabetic agents
US6861440B2 (en) 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
US20030125304A1 (en) 2001-11-09 2003-07-03 Hans-Ulrich Demuth Substituted amino ketone compounds
WO2003045977A2 (en) 2001-11-26 2003-06-05 Trustees Of Tufts College Peptidomimetic Inhibitors of Post-Proline Cleaving Enzymes
CA2466870A1 (en) 2001-11-26 2003-06-05 Trustees Of Tufts College Methods for treating autoimmune disorders, and reagents related thereto
WO2003057144A2 (en) 2001-12-26 2003-07-17 Guilford Pharmaceuticals Change inhibitors of dipeptidyl peptidase iv
US6727261B2 (en) 2001-12-27 2004-04-27 Hoffman-La Roche Inc. Pyrido[2,1-A]Isoquinoline derivatives
WO2003072528A2 (en) 2002-02-08 2003-09-04 Idun Pharmaceuticals, Inc. (substituted)acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
ES2345096T3 (en) 2002-02-13 2010-09-15 F. Hoffmann-La Roche Ag NEW DERIVATIVES OF PIRIDINA AND PIRIMIDINA.
CN1308311C (en) 2002-02-13 2007-04-04 霍夫曼-拉罗奇有限公司 Novel pyridine- and quinoline-derivatives
US6906074B2 (en) 2002-02-22 2005-06-14 Nippon Zoki Pharmaceutical Co., Ltd. 2-phenylpiperazine derivatives
JP2004043429A (en) 2002-02-25 2004-02-12 Eisai Co Ltd New xanthine derivative and dppiv inhibitor
DE60304911D1 (en) 2002-02-25 2006-06-08 Eisai Co Ltd Xanthine derivatives as DPP-IV inhibitors
EA007434B1 (en) 2002-02-28 2006-10-27 Прозидион Лимитед Glutaminyl based dpiv inhibitors
HUP0200849A2 (en) * 2002-03-06 2004-08-30 Sanofi-Synthelabo N-aminoacetyl-pyrrolidine-2-carbonitrile derivatives, pharmaceutical compositions containing them and process for producing them
EP1490335B1 (en) 2002-03-25 2007-09-19 Merck & Co., Inc. Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2003080633A1 (en) 2002-03-25 2003-10-02 Nippon Kayaku Kabushiki Kaisha Novel $g(a)-amino-n-(diaminophosphinyl)lactam derivative
JP4329381B2 (en) 2002-04-04 2009-09-09 田辺三菱製薬株式会社 Pharmaceutical composition
JP4329382B2 (en) 2002-04-04 2009-09-09 田辺三菱製薬株式会社 Pharmaceutical composition
JP2005532283A (en) 2002-04-08 2005-10-27 トレント・ファーマシューティカルズ・リミテッド Thiazolidine-4-carbonitrile and the like and their use as dipeptidyl-peptidase inhibitors
JP2003300977A (en) 2002-04-10 2003-10-21 Sumitomo Pharmaceut Co Ltd Xanthine derivative
JP2004026820A (en) 2002-05-09 2004-01-29 Taisho Pharmaceut Co Ltd Dipeptidyl peptidase iv inhibitor
JP2003327532A (en) 2002-05-10 2003-11-19 Takeda Chem Ind Ltd Peptidase inhibitor
US6710040B1 (en) 2002-06-04 2004-03-23 Pfizer Inc. Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors
WO2003101449A2 (en) 2002-06-04 2003-12-11 Pfizer Products Inc. Process for the preparation of 3,3,4,4-tetrafluoropyrrolidine and derivatives thereof
NZ536794A (en) 2002-06-06 2007-04-27 Eisai Co Ltd Condensed imidazole derivatives
JP2004026678A (en) 2002-06-24 2004-01-29 Microbial Chem Res Found Therapeutic agent for type 2 diabetes
US6833973B2 (en) 2002-06-27 2004-12-21 International Business Machines Corporation Apparatus and method to calibrate a servo sensor
DE60330485D1 (en) 2002-07-15 2010-01-21 Merck & Co Inc FOR THE TREATMENT OF DIABETES
JP4542757B2 (en) 2002-08-08 2010-09-15 武田薬品工業株式会社 Fused heterocyclic compounds
WO2004034968A2 (en) * 2002-08-20 2004-04-29 The Regents Of The University Of California Combination therapy for controlling appetites
DE10238243A1 (en) 2002-08-21 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg New 8-(3-amino-piperidin-1-yl)-xanthine derivatives are dipeptidylpeptidase-IV inhibitors useful for, e.g. treating diabetes mellitus, arthritis or obesity
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DE10238477A1 (en) 2002-08-22 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg New purine derivatives, their production and their use as medicines
DE10238470A1 (en) 2002-08-22 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg New xanthine derivatives, their production and their use as medicines
US20060039974A1 (en) 2002-09-11 2006-02-23 Takeda Pharmaceutical Company Limited Sustained release preparation
WO2004024943A1 (en) 2002-09-11 2004-03-25 Yamanouchi Pharmaceutical Co., Ltd. Method of screening insulin content enhancer
US7482337B2 (en) 2002-11-08 2009-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10251927A1 (en) 2002-11-08 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg New 1,7,8-trisubstituted xanthine derivatives, are dipeptidylpeptidase-IV inhibitors useful e.g. for treating diabetes mellitus type I or II, arthritis or obesity
JP2006508975A (en) 2002-11-18 2006-03-16 ファイザー・プロダクツ・インク Fluorinated cyclic amides that inhibit dipeptidyl peptidase IV
DE10256264A1 (en) 2002-12-03 2004-06-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg New trisubstituted dihydro-imidazo-pyridazinone or imidazo-pyridinone derivatives, useful as dipeptidylpeptidase-IV inhibitors for e.g. treating diabetes mellitus type I or II, arthritis or obesity
CA2508487A1 (en) 2002-12-04 2004-06-17 Merck & Co., Inc. Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
JP4504924B2 (en) 2002-12-20 2010-07-14 メルク・シャープ・エンド・ドーム・コーポレイション 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment and prevention of diabetes
RS20050532A (en) 2003-01-14 2007-12-31 Arena Pharmaceuticals Inc., 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
US7265128B2 (en) 2003-01-17 2007-09-04 Merck & Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
JP2004244412A (en) 2003-01-20 2004-09-02 Kotobuki Seiyaku Kk 2-cyanopyrrolidine derivative having substituent at 4-position, method for producing the same, and medicament containing the same
CA2513684A1 (en) 2003-01-31 2004-08-19 Merck & Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
PL378295A1 (en) 2003-02-24 2006-03-20 Arena Pharmaceuticals, Inc. Substituted aryl and heteroaryl derivatives as modulators of glucose metabolism and the prophylaxis and treatment of disorders thereof
JP2004269469A (en) 2003-03-12 2004-09-30 Yamanouchi Pharmaceut Co Ltd Pyrimidine derivative or salt thereof
JP2004269468A (en) 2003-03-12 2004-09-30 Yamanouchi Pharmaceut Co Ltd Pyrimidine derivative or salt thereof
ATE462432T1 (en) 2003-05-05 2010-04-15 Probiodrug Ag GLUTAMINYL CYCLASE INHIBITORS
US7083933B1 (en) 2003-05-09 2006-08-01 Prosidion Limited Methods for identification of modulators of OSGPR116 activity
CA2524531A1 (en) 2003-05-14 2004-12-02 Merck And Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2004103993A1 (en) 2003-05-14 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
US20060293297A1 (en) 2003-05-15 2006-12-28 Hiroshi Fukushima Cyanofluoropyrrolidine derviative
DE10327439A1 (en) 2003-06-18 2005-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel imidazopyridazinone and imidazopyridone derivatives, their production and their use as pharmaceuticals
BRPI0411713B8 (en) 2003-06-20 2021-05-25 Hoffmann La Roche compounds, process for their manufacture, pharmaceutical compositions comprising them, method for treatment and/or prophylaxis of diseases that are associated with dpp-iv and their use
AU2004251829B2 (en) 2003-06-20 2009-12-17 F. Hoffmann-La Roche Ag Hexahydropyridoisoqinolines as DPP-IV inhibitors
JP2005019000A (en) 2003-06-23 2005-01-20 Inter Media:Kk Illumination control system
JO2625B1 (en) 2003-06-24 2011-11-01 ميرك شارب اند دوم كوربوريشن Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
JP2005018412A (en) 2003-06-26 2005-01-20 Toppan Printing Co Ltd Electronic purchasing system and method
JP2005023038A (en) 2003-07-04 2005-01-27 Taisho Pharmaceut Co Ltd Therapeutic agent for chronic renal disease
MXPA06000554A (en) 2003-07-14 2006-07-03 Arena Pharm Inc Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto.
DE10333935A1 (en) 2003-07-25 2005-02-24 Aventis Pharma Deutschland Gmbh New bicyclic cyano-heterocycles, process for their preparation and their use as pharmaceuticals
US7094800B2 (en) 2003-07-25 2006-08-22 Sanofi-Aventis Deutschland Gmbh Cyanopyrrolidides, process for their preparation and their use as medicaments
US7008957B2 (en) 2003-07-25 2006-03-07 Sanofi-Aventis Deutschland Gmbh Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments
US6995183B2 (en) 2003-08-01 2006-02-07 Bristol Myers Squibb Company Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
WO2005019168A2 (en) 2003-08-20 2005-03-03 Pfizer Products Inc. Fluorinated lysine derivatives as dipeptidyl peptidase iv inhibitors
EP1659123A1 (en) 2003-08-29 2006-05-24 Dainippon Sumitomo Pharma Co., Ltd. Bicyclic pyrazole derivative
HU227684B1 (en) 2003-08-29 2011-11-28 Sanofi Aventis Adamantane and azabicyclo-octane and nonane derivatives and their use as dpp-iv inhibitors
EP1671649B1 (en) 2003-10-03 2011-11-23 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase IV inhibitors for treating diabetic patients with sulfonylurea secondary failure
DE10355304A1 (en) * 2003-11-27 2005-06-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel 8- (piperazin-1-yl) and 8 - ([1,4] diazepan-1-yl) xanthines, their preparation and their use as pharmaceuticals
US7217711B2 (en) * 2003-12-17 2007-05-15 Boehringer Ingelheim International Gmbh Piperazin-1-yl and 2-([1,4]diazepan-1-yl)-imidazo[4,5-d]-pyridazin-4-ones, the preparation thereof and their use as pharmaceutical compositions
NZ547965A (en) 2003-12-24 2009-12-24 Prosidion Ltd 1,2,4-Oxadiazole derivatives as GPCR receptor agonists
US7501426B2 (en) * 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004009039A1 (en) * 2004-02-23 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8- [3-Amino-piperidin-1-yl] xanthines, their preparation and use as pharmaceuticals
ATE415397T1 (en) 2004-06-04 2008-12-15 Arena Pharm Inc SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND FOR THE PROPHYLAXIS AND TREATMENT OF RELATED DISEASES
WO2006000577A2 (en) 2004-06-24 2006-01-05 Galapagos N.V. Lxr agonists to promote bone homeostasis
US20060024313A1 (en) 2004-07-06 2006-02-02 Xin Chen Agents that disrupt dimer formation in DPP-IV family of prolyl dipeptidases
WO2006019965A2 (en) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US20060046978A1 (en) 2004-08-31 2006-03-02 Morphochem Ag Novel compounds that inhibit dipeptidyl peptidase (DPP-IV) and neprilysin (NEP) and/or angiotensin converting enzyme (ACE)
DE102004044221A1 (en) 2004-09-14 2006-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg New 3-methyl-7-butynyl xanthines, their preparation and their use as pharmaceuticals
CN101048368A (en) * 2004-10-07 2007-10-03 默克公司 Acyclic hydrazides as cannabinoid receptor modulators
CA2583259C (en) 2004-10-08 2011-08-02 Astellas Pharma Inc. Aromatic ring fused pyrimidine derivative
TW200621257A (en) 2004-10-20 2006-07-01 Astellas Pharma Inc Pyrimidine derivative fused with nonaromatic ring
US7411093B2 (en) 2004-12-20 2008-08-12 Hoffman-La Roche Inc. Aminocycloalkanes as DPP-IV inhibitors
EP1828192B1 (en) 2004-12-21 2014-12-03 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CA2591922A1 (en) 2004-12-24 2006-06-29 Prosidion Limited G-protein coupled receptor (gpr116) agonists and use thereof for treating obesity and diabetes
US8193359B2 (en) 2004-12-24 2012-06-05 Prosidion Limited G-protein coupled receptor agonists
US7589088B2 (en) 2004-12-29 2009-09-15 Bristol-Myers Squibb Company Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
GB0428514D0 (en) 2004-12-31 2005-02-09 Prosidion Ltd Compounds
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
DOP2006000008A (en) 2005-01-10 2006-08-31 Arena Pharm Inc COMBINED THERAPY FOR THE TREATMENT OF DIABETES AND RELATED AFFECTIONS AND FOR THE TREATMENT OF AFFECTIONS THAT IMPROVE THROUGH AN INCREASE IN THE BLOOD CONCENTRATION OF GLP-1
US20070032420A1 (en) 2005-02-09 2007-02-08 Entelos, Inc. Treating diabetes with glucagon-like peptide-1 secretagogues
EP1902730A4 (en) 2005-06-09 2009-11-11 Banyu Pharma Co Ltd Npy y2 agonist for use as therapeutic agent for disease accompanied by diarrhea
JP5114395B2 (en) 2005-06-30 2013-01-09 プロシディオン・リミテッド GPCR agonist
AU2006264651A1 (en) 2005-06-30 2007-01-11 Prosidion Limited G-protein coupled receptor agonists
BRPI0613505A2 (en) 2005-06-30 2011-01-11 Prosidion Ltd gpcr agonists
EP1907384A2 (en) 2005-06-30 2008-04-09 Prosidion Limited Gpcr agonists
US7708191B2 (en) * 2005-07-28 2010-05-04 Edwin Vega Telebanking apparatus for transferring money or cash value between two parties in the same country or across national borders, for paying bills and browsing the internet
PE20071221A1 (en) 2006-04-11 2007-12-14 Arena Pharm Inc GPR119 RECEPTOR AGONISTS IN METHODS TO INCREASE BONE MASS AND TO TREAT OSTEOPOROSIS AND OTHER CONDITIONS CHARACTERIZED BY LOW BONE MASS, AND COMBINED THERAPY RELATED TO THESE AGONISTS
EP1971862B1 (en) 2006-04-11 2010-11-10 Arena Pharmaceuticals, Inc. Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual
US20080103123A1 (en) 2006-08-30 2008-05-01 Biovitrum New compounds
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410508B1 (en) * 1998-10-07 2002-06-25 Med College Georgia Res Inst Glucose-dependent insulinotropic peptide for use as an osteotropic hormone
WO2001087929A2 (en) * 2000-05-18 2001-11-22 Bayer Aktiengesellschaft Regulation of human dopamine-like g protein-coupled receptor
WO2005007647A1 (en) * 2003-07-11 2005-01-27 Arena Pharmaceuticals, Inc. Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MAYET S ET AL: "GPR119 activation increases glucose-dependent insulin secretion in insulin-producing cells and isolated rat islets", DIABETOLOGIA, vol. 48, no. Suppl. 1, 2005, & 41ST ANNUAL MEETING OF THE EUROPEAN-ASSOCIATION-FOR-THE-STUDY-OF-DIAB ETES; ATHENS, GREECE; SEPTEMBER 10 -15, 2005, pages A166, XP002449852, ISSN: 0012-186X *
OVERTON HILARY A ET AL: "Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents", CELL METABOLISM, vol. 3, no. 3, March 2006 (2006-03-01), pages 167 - 175 URL, XP002449851, ISSN: 1550-4131 *

Also Published As

Publication number Publication date
JP4762359B2 (en) 2011-08-31
EP1971862A2 (en) 2008-09-24
EP2369341A2 (en) 2011-09-28
US8017574B2 (en) 2011-09-13
AR060406A1 (en) 2008-06-11
JP2009254375A (en) 2009-11-05
ZA200807997B (en) 2011-05-25
ECSP088817A (en) 2008-11-27
BRPI0710597A2 (en) 2012-06-19
KR101281962B1 (en) 2013-07-08
US8026212B2 (en) 2011-09-27
US20100203038A1 (en) 2010-08-12
US20120059166A1 (en) 2012-03-08
US8580526B2 (en) 2013-11-12
CN103323606A (en) 2013-09-25
EP2369341A3 (en) 2012-01-04
CN101421618B (en) 2013-11-20
RS51745B (en) 2011-10-31
NO20084746L (en) 2009-01-09
AU2007238805A1 (en) 2007-10-25
EP2410330A2 (en) 2012-01-25
SG10201404220TA (en) 2014-10-30
EA201101475A1 (en) 2012-07-30
DK1971862T3 (en) 2011-02-14
JP2011101640A (en) 2011-05-26
PL1971862T3 (en) 2011-04-29
MA30555B1 (en) 2009-07-01
JP2009240328A (en) 2009-10-22
EP1971862B1 (en) 2010-11-10
HK1117911A1 (en) 2009-01-23
GT200800207A (en) 2010-03-09
NZ571110A (en) 2011-03-31
ES2354390T3 (en) 2011-03-14
JP2011103887A (en) 2011-06-02
PT1971862E (en) 2011-02-14
CL2007001011A1 (en) 2008-05-16
US7833730B2 (en) 2010-11-16
TWI409458B (en) 2013-09-21
TNSN08396A1 (en) 2010-04-14
TW200809200A (en) 2008-02-16
CA2618488C (en) 2010-07-13
EP2402750A1 (en) 2012-01-04
US8026074B2 (en) 2011-09-27
WO2007120689A2 (en) 2007-10-25
CR10337A (en) 2009-01-19
JP5415856B2 (en) 2014-02-12
JP4521838B2 (en) 2010-08-11
EP2410330A3 (en) 2012-06-13
ATE487940T1 (en) 2010-11-15
CY1111123T1 (en) 2015-06-11
US20100068700A1 (en) 2010-03-18
US20100203577A1 (en) 2010-08-12
MEP27308A (en) 2010-06-10
CA2618488A1 (en) 2007-10-25
AU2007238805B2 (en) 2012-04-05
EA200870424A1 (en) 2009-06-30
HRP20110068T1 (en) 2011-02-28
CN101421618A (en) 2009-04-29
CN103536924A (en) 2014-01-29
JP2011072312A (en) 2011-04-14
EA016041B1 (en) 2012-01-30
US20100203037A1 (en) 2010-08-12
UA97479C2 (en) 2012-02-27
DE602007010420D1 (en) 2010-12-23
KR20090007409A (en) 2009-01-16
MX2008013120A (en) 2008-10-27
SI1971862T1 (en) 2011-02-28
JP2009533055A (en) 2009-09-17

Similar Documents

Publication Publication Date Title
WO2007120689A3 (en) Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual
WO2007120702A3 (en) Use of gpr119 receptor agonists for increasing bone mass and for treating osteoporosis, and combination therapy relating thereto
WO2007092622A3 (en) Compositions and methods for treating bone
WO2008008887A3 (en) Gpr119 agonists for treating metabolic disorders
WO2009117421A3 (en) Heterocyclic modulators of gpr119 for treatment of disease
WO2006009836A3 (en) Tdf-related compounds and analogs thereof
WO2008064351A3 (en) (r)-n-stereoisomers of 7,8-saturated-4,5-epoxy-morphinanium analogs
WO2008021851A3 (en) Novel compounds as antagonists or inverse agonists for opioid receptors
WO2007111864A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2009052431A3 (en) Cd19 binding agents and uses thereof
WO2007136577A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2007146965A3 (en) Compounds for the treatment of periodontal disease
SI1984357T1 (en) 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases
WO2005079756A3 (en) Combination of a nmda receptor antagonist and an anti-depressive drug mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions
UA96308C2 (en) Glucagon receptor antagonist compounds, composition comprising such compounds and use thereof
WO2007076070A3 (en) Modulators of muscarinic receptors
EP2076116A4 (en) Compositions, methods, and devices for treating liver disease
MX2009006345A (en) Compounds useful as protein kinase inhibitors.
WO2008076243A3 (en) Acyl bipiperidinyl compounds, compositions containing such compounds and methods of treatment
WO2008034142A3 (en) Synthesis, methods of using, and compositions of cycloalkylmethylamines
JO2645B1 (en) Compounds
WO2008027600A3 (en) Imatinib compositions
WO2007095161A3 (en) Methods and compositions for treating disorders associated with increased bone turnover and osteopenia
GB0611907D0 (en) Compounds
WO2007035872A3 (en) Tdf-related compounds and analogs thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2007755238

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11989037

Country of ref document: US

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07755238

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2618488

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2009505445

Country of ref document: JP

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 571110

Country of ref document: NZ

Ref document number: 2007238805

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 194215

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 12008502104

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 08103377

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 2007238805

Country of ref document: AU

Date of ref document: 20070410

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: CR2008-010337

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 200780012714.2

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/013120

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2008101674

Country of ref document: EG

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 4184/KOLNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: DZP2008000656

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 1020087027461

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 10970

Country of ref document: GE

WWE Wipo information: entry into national phase

Ref document number: 200870424

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: P-2011/0039

Country of ref document: RS

ENP Entry into the national phase

Ref document number: PI0710597

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20081009